MedMira Awarded China Patent
Rapid Flow-Through Technology Patents in Three Major Global Markets
MedMira Inc. announced that it received a Notice on Grant of Patent Right For Invention (equivalent to the Notice of Allowance in the United States) from the State Intellectual Property Office (SIPO) of the People's Republic of China for its rapid diagnostic device and assay (Chinese Patent Application No. 02819646.5). The novel invention is the rapid flow-through technology (RFT) platform, the core product engine upon which the company has built its successful line of rapid tests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's IP "triple crown" along with similar patents awarded in the United States (Patent Application No. 10/163,675) and the European Union (European Patent No. EP1417489).
"Patents on our core technology in three major global markets are fundamental components of our plan to grow our business through strategic partnerships. While we continue to pursue patent protection for our progressive IP estate in additional markets, we can now fully engage in collaborative relationships to tap opportunities in three of the most lucrative markets of the $40 billion global diagnostics market," said Hermes Chan, President and CEO, MedMira Inc. "These partnerships, taking shape in various forms including licensing, commercialization, and contract manufacturing, will enable both new business and new innovation opportunities for MedMira."
Other news from the department research and development
